Press Release   Theralase Compound Highly Effective in Destroying Bladder Cancer Tumour CellsToronto, Ontario –November 12...
Press Releasehttp://www.sunpharma.com/news/press/20121108%20Sun%20Pharma%20to%20Acquire%20DUSA%20.pdfAbout Theralase Techn...
Upcoming SlideShare
Loading in …5
×

Theralase Compounds Destroy Bladder Cancer

233 views
170 views

Published on

Theralase's Photo Dynamic Therapy (PDT) Division, announced today study results proving that its patented Photo Dynamic Compounds (PDCs) were significantly more effective in destroying a human urinary bladder carcinoma cell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
233
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Theralase Compounds Destroy Bladder Cancer

  1. 1. Press Release Theralase Compound Highly Effective in Destroying Bladder Cancer Tumour CellsToronto, Ontario –November 12, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) Photo DynamicTherapy (PDT) Division, announced today study results proving that its patented Photo DynamicCompounds (PDCs) were significantly more effective in destroying a human urinary bladder carcinomacell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated, “Commercialization of any new anti-cancer medicine depends upon the safe and effective destruction of all cancerous tumours, whileupholding the patient’s quality of life. We are excited that our leading compound effectively destroyeda human urinary bladder carcinoma cell line (HT-1376) when activated by our proprietary light system.To validate our initial success, we evaluated the efficacy of the Theralase PDC in comparison withaminolevulinic acid (ALA). The results indicated that the Theralase PDC was effectively destroyingbladder cancer cells at much lower concentrations than ALA (1/1000th of the dose).”Dr. Lothar Lilge, Professor and Senior Scientist, Ontario Cancer Institute, Princess Margaret CancerCentre, University Health Network stated, “In my lab, the Theralase PDCs have shown remarkableefficacy and robustness in the destruction of various cancer cell lines, such as: colon, brain, breast andnow bladder cancer. This research potentially offers a new opportunity for individualized cancertherapy across various invasive tumours.”Roger Dumoulin-White, President and CEO, Theralase Inc. stated, “Based upon our recent success, wehave now reconfirmed that bladder cancer is our lead cancer target for our lead PDC compound. Ourresearch confirms what we had already suspected; our PDC technology is lethal to human urinarybladder carcinoma cells. Given that our technology can deliver effective results at significantly lowerdoses than ALA, this would suggest a superior safety and cost effectiveness for our lead compound, ascompared to ALA. We are confident that as we complete our preclinical research and prepare forhuman trials in 2013, we will demonstrate to the medical community that we possess a highlyeffective, safe and efficient alternative treatment option to current bladder cancer patients.”Bladder cancer is the fifth most common cancer in the North America; the fourth most common amongmen and eighth most common in women. In the United States 73,000 new bladder cancer cases and15,000 deaths are reported annually. With a recurrence rate of nearly 80%, bladder cancer is the mostexpensive cancer to treat on a per patient basis. The high recurrence rate severely affects the quality oflife of patients and also the total cost of treatment, which in the United States exceeds $2.9 billion indirect treatment related costs annually.In other related news, Sun Pharmaceutical Industries (NSE: SUNPHARMA, BSE: 524715), with a marketvalue of $USD 13.3 billion, announced on November 8, 2012, that it signed a definitive agreement toacquire Dusa Pharaceuticals Inc. (DUSA) for $8 per share for a total cash consideration of $USD 230million. DUSA is a dermatology company focused on developing and marketing its FDA approvedLevulan photodynamic therapy platform (active ingredient of Levulan is ALA), for actinic keratosis ofthe face or scalp (dry, scaly patches on the skin that can lead to skin cancer).
  2. 2. Press Releasehttp://www.sunpharma.com/news/press/20121108%20Sun%20Pharma%20to%20Acquire%20DUSA%20.pdfAbout Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralasetechnology is safe and effective in treating pain, inflammation and for tissue regeneration of neuralmuscular skeletal conditions and wound healing. Theralase is currently developing patented PhotoDynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses whenlight activated by Theralase’s proprietary and patented laser technology.For further information please visit www.theralase.com , regulatory filings may be viewed by visitingwww.sedar.com.This press release contains forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation toupdate these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More InformationRoger Dumoulin-WhitePresident & CEO416-447-8455 ext. 225rwhite@theralase.comKristina HacheyChief Financial Officer416-447-8455 ext. 224khachey@theralase.comArkady MandelChief Scientific Officer416-447-8455 ext. 242amandel@theralase.comGreg BewshDirector of Investor Relations416-447-8455 ext. 262gbewsh@theralase.com

×